A new approach to treating renal anaemia
- PMID: 31511661
- DOI: 10.1038/s41581-019-0207-7
A new approach to treating renal anaemia
Comment on
-
Roxadustat Treatment for Anemia in Patients Undergoing Long-Term Dialysis.N Engl J Med. 2019 Sep 12;381(11):1011-1022. doi: 10.1056/NEJMoa1901713. Epub 2019 Jul 24. N Engl J Med. 2019. PMID: 31340116 Clinical Trial.
References
-
- Chen, N. et al. Roxadustat treatment for anemia in patients undergoing long-term dialysis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1901713 (2019). - DOI - PubMed - PMC
-
- Chen, N. et al. Roxadustat for anemia in patients with kidney disease not receiving dialysis. N. Engl. J. Med. https://doi.org/10.1056/NEJMoa1813599 (2019). - DOI - PubMed - PMC
-
- Winearls, C. G. et al. Effect of human erythropoietin derived from recombinant DNA on the anaemia of patients maintained by chronic haemodialysis. Lancet 2, 1175–1178 (1986). - DOI
-
- Eschbach, J. W. et al. Recombinant human erythropoietin in anemic patients with end-stage renal disease. Results of a phase III multicenter clinical trial. Ann. Intern. Med. 111, 992–1000 (1989). - DOI
-
- Whoriskey, P. Anemia drug made billions, but at what cost? The Washington Post https://www.washingtonpost.com/business/economy/anemia-drug-made-billion... (2012).
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical